Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

Related Keywords

Georgia ,United States ,Atlanta ,Roland Chen ,Global Drug Development For Bristol Myers Squibb ,American College Of Cardiology ,Neuroscience Development ,Bristol Myers Squibb ,American College ,Scientific Session ,Senior Vice President ,Global Drug Development ,Bristol Myers ,Risk Evaluation ,Mitigation Strategy ,